Cerebral Artery OcclusionNTFNCT02880579
Neurothrombectomy France
An observational study of Cerebral Artery Occlusion, run by Nantes University Hospital at 1 site in France.
Trial summary
The Ischemic Brain Vascular Accident (CVA) is a major public health issue. An Early and appropriate charging anyone with stroke is essential to reduce mortality, reduce dependency and promote recovery of autonomy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cerebral Artery Occlusion
- How many people
- 230 participants
- Where
- 1 siteFrance
- Study dates
- May 2013to Mar 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 200 consecutive patients admitted to a stroke unit for cerebral infarction treated by thrombectomy included (with or without fibrinolysis by intra venous) prospectively over a period of 1 year and 3 months followed for clinical neurological assessment (primary endpoint) .
Who may be able to join
- Signature of the information notice by the patient or his legal representative
- Age> 18 years
- Clinical and imaging consistent with ischemic stroke whose symptoms start back within 8h
- Thrombosis (TICI 0 or 1) of the carotid T, M1, M1-M2 bifurcation of the basilar artery occlusion in TANDEM ACI / M1.
Who cannot join
- Pregnant or lactating women
- Rapid improvement of NIHSS (gain of more than 4 points) between two pre-treatment assessments.
- ASPECT score <7 on the scanner or <5 on the diffusion-weighted imaging (DWI)
- Intracranial hemorrhage on imaging
- Inability of clinical evaluations at 3 months
- extensive lesions of the brain stem (the presence of a complete section of the brainstem hyperintense b1000)
- 0 Refusal to participate in the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Clinical Results of Treatment of Cerebral Artery Occlusion by Mechanical Thrombectomy, in the Acute Phase of Stroke
The Ischemic Brain Vascular Accident (CVA) is a major public health issue. An Early and appropriate charging anyone with stroke is essential to reduce mortality, reduce dependency and promote recovery of autonomy. Intravenous fibrinolysis in patients with cerebral infarction (NINDS 1995), is reserved for a small proportion of highly selected patients. It therefore remains a significant therapeutic challenge, especially for patients with against-indications to fibrinolysis or in whom there is no immediate benefit. For twenty years of mechanical devices have been developed to remove, as quickly as possible, the cause of intracranial arterial occlusion and allow restoration of blood flow before brain damage is irreversible.
NTF The protocol is part of the evaluation process of our clinical practices recommended by the National Health Authority (HAS), in the specific context of mechanical thrombectomy performed in French centers of interventional neuroradiology working with neurovascular units (A V).
- Conditions
- Cerebral Artery Occlusion
What is being measured
The primary outcome is the main question the study is designed to answer.
clinical score for handicap (mRS)
Measured: at 3 months
Secondary outcomes (23)
hemorrhagic complications on postoperative imaging
Measured: baseline
hemorrhagic complications on postoperative imaging
Measured: at 1 day
physiological parameter : age
Factors of good clinical prognosis
Measured: baseline
presence of coronary artery disease
Factors of good clinical prognosis
Measured: baseline
presence of arterial hypertension
Factors of good clinical prognosis
Measured: baseline
presence of diabetes
Factors of good clinical prognosis
Measured: baseline
presence of hypercholesterolemia
Factors of good clinical prognosis
Measured: baseline
presence of intracranial stenosis
Factors of good clinical prognosis
Measured: baseline
presence of occlusive arterial disease
Factors of good clinical prognosis
Measured: baseline
presence of haematological disorders
Factors of good clinical prognosis
Measured: baseline
presence of neoplasia
Factors of good clinical prognosis
Measured: baseline
NIHSS score
Factors of good clinical prognosis
Measured: baseline
ASPECTS score
Factors of good clinical prognosis
Measured: baseline
MRI imaging of stroke
Factors of good clinical prognosis
Measured: baseline
unblocking rate based on the score TICI
Measured: at 3 months
NIHSS evaluation
Measured: at 24h
Influence of collaterality score on the NIHSS
Measured: at 24h
Influence ASPECTS score on the NIHSS
Measured: at 24h
Influence ASPECTS score on the NIHSS
Measured: at 3months
influence of anesthesia on the NIHSS
Measured: at 24h
hemorrhagic complications
Measured: at 24h
Influence of hemorrhagic complications on NIHSS
Measured: at 24h
Influence of hemorrhagic complications on NIHSS
Measured: at 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2016 (estimated)
- Study startMay 2013
- Primary completionMar 2015
- Study completionMar 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral Artery OcclusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 230 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nantes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hubert DESAL, PU-PH, Principal investigator, Nantes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02880579
- Sponsor's protocol ID
- RC11_0097
- Acronym
- NTF
- Status last verified
- Aug 2016
- First submitted
- 5 Aug 2016
- Last updated
- 24 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Clinical Results of Treatment of Cerebral Artery Occlusion by Mechanical Thrombectomy, in the Acute Phase of Stroke
- ClinicalTrials.gov ID
- NCT02880579
- Acronym / sponsor ID
- NTF / RC11_0097
- Conditions
- Cerebral Artery Occlusion
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 230 participants (actual)
- Lead sponsor
- Nantes University HospitalUniversity, hospital or other
- Study start
- May 2013
- Primary completion
- Mar 2015 (actual)
- Study completion
- Mar 2015 (actual)
- First posted
- 26 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Ischemic Brain Vascular Accident (CVA) is a major public health issue. An Early and appropriate charging anyone with stroke is essential to reduce mortality, reduce dependency and promote recovery of autonomy. Intravenous fibrinolysis in patients with cerebral infarction (NINDS 1995), is reserved for a small proportion of highly selected patients. It therefore remains a significant therapeutic challenge, especially for patients with against-indications to fibrinolysis or in whom there is no immediate benefit. For twenty years of mechanical devices have been developed to remove, as quickly as possible, the cause of intracranial arterial occlusion and allow restoration of blood flow before brain damage is irreversible.
NTF The protocol is part of the evaluation process of our clinical practices recommended by the National Health Authority (HAS), in the specific context of mechanical thrombectomy performed in French centers of interventional neuroradiology working with neurovascular units (A V).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 200 consecutive patients admitted to a stroke unit for cerebral infarction treated by thrombectomy included (with or without fibrinolysis by intra venous) prospectively over a period of 1 year and 3 months followed for clinical neurological assessment (primary endpoint) .
Key inclusion criteria (4 listed)
- Signature of the information notice by the patient or his legal representative
- Age> 18 years
- Clinical and imaging consistent with ischemic stroke whose symptoms start back within 8h
- Thrombosis (TICI 0 or 1) of the carotid T, M1, M1-M2 bifurcation of the basilar artery occlusion in TANDEM ACI / M1.
Key exclusion criteria (7 listed)
- Pregnant or lactating women
- Rapid improvement of NIHSS (gain of more than 4 points) between two pre-treatment assessments.
- ASPECT score <7 on the scanner or <5 on the diffusion-weighted imaging (DWI)
- Intracranial hemorrhage on imaging
- Inability of clinical evaluations at 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
clinical score for handicap (mRS)
Time frame: at 3 months
23 secondary outcomes
hemorrhagic complications on postoperative imaging
Time frame: baseline
hemorrhagic complications on postoperative imaging
Time frame: at 1 day
physiological parameter : age
Time frame: baseline
presence of coronary artery disease
Time frame: baseline
presence of arterial hypertension
Time frame: baseline
presence of diabetes
Time frame: baseline
presence of hypercholesterolemia
Time frame: baseline
presence of intracranial stenosis
Time frame: baseline
presence of occlusive arterial disease
Time frame: baseline
presence of haematological disorders
Time frame: baseline
presence of neoplasia
Time frame: baseline
NIHSS score
Time frame: baseline
ASPECTS score
Time frame: baseline
MRI imaging of stroke
Time frame: baseline
unblocking rate based on the score TICI
Time frame: at 3 months
NIHSS evaluation
Time frame: at 24h
Influence of collaterality score on the NIHSS
Time frame: at 24h
Influence ASPECTS score on the NIHSS
Time frame: at 24h
Influence ASPECTS score on the NIHSS
Time frame: at 3months
influence of anesthesia on the NIHSS
Time frame: at 24h
hemorrhagic complications
Time frame: at 24h
Influence of hemorrhagic complications on NIHSS
Time frame: at 24h
Influence of hemorrhagic complications on NIHSS
Time frame: at 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cerebral Artery Occlusion
Not yet recruiting
SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions
Medium Vessel Occlusion Stroke (MeVO), Stroke Acute
Recruiting
Extracranial-intracranial Bypass Surgery for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial
Symptomatic Chronic Middle Cerebral Artery Occlusion, Infarction, Middle Cerebral Artery
RecruitingObservational study
Registry of Multicenter Brain-Heart Comorbidity in China
Ischemic Heart Disease, Cardiac Arrest
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hubert DESAL, PU-PH principal investigator
Nantes University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebral Artery Occlusion, run by Nantes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
clinical score for handicap (mRS) (time frame: at 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026; AzTrials last refreshed its copy on 31 Oct 2026.